Runbo Zhong

24PUBLICATIONS
34CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Medical infection agents (incl. prions)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|Jul 08, 2026
In vivo engineering tumor cells to a universal "all-in-one" cancer vaccine with full antigen spectrum.

|Jun 15, 2026
Efficacy and safety of first-line oral vinorelbine plus firmonertinib in refractory EGFR-mutated non-small cell lung cancer: study protocol of a multicenter, non-randomized, two-cohort study.

|May 25, 2026
Durvalumab plus anlotinib versus durvalumab alone as maintenance treatment in extensive-stage small-cell lung cancer (DURABLE): a multicenter, randomized, phase II trial and biomarker analysis.

|May 15, 2026
PD-L1 expression is associated with inferior outcomes independent of EGFR subtype in advanced non-small cell lung cancer with uncommon EGFR mutations treated with first-line second-generation EGFR-tyrosine kinase inhibitors.

|Apr 04, 2026
RIPK3 sequentially recruits MLKL and RIPK1 to induce PANoptosis and chemokine production.

Yu Yang, Yue Wang, Yang Wang

|Feb 04, 2026
Efficacy of first-line immunochemotherapy across KRAS mutation subtypes in advanced lung adenocarcinoma.

Hongping Jin, Honglei Huang, Yiqing Wu

Pageof 4

Frequent Collaborators

8 joint publications

Baohui Han

4 joint publications

Yingqi Xu

3 joint publications

Yuqing Lou

3 joint publications

Hongping Jin